Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
FD

NASDAQ · FDMT

4D Molecular Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$14.18

Down-$0.69 (-4.87%)

Updated Sep 10, 2026, 11:33 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
510.45M
P/E ratio
-2.93
Dividend yield
0.00%
52-week range
$6.47 – $16.93
Volume
493.77K
Avg. volume
843.04K

Price performance

FDMT price history

1M range · 19 trading sessions · Daily adjusted prices

FDMT closed at $14.18 after 19 trading sessions, up 21.72% for the selected period.

Last close
$14.18
Period change
+21.72%
Period low
$11.65
Period high
$16.76
Daily close
View OHLC price history
FDMT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$14.44$14.50$14.085$14.18493.77K
Sep 8, 2026$14.57$15.29$14.1326$14.63542.04K
Sep 4, 2026$14.50$15.00$14.3301$14.97420.64K
Sep 3, 2026$14.94$14.94$14.275$14.70782.45K
Sep 2, 2026$14.40$15.13$14.08$14.941.04M
Sep 1, 2026$13.94$14.85$13.80$14.35707.96K
Aug 31, 2026$14.49$14.60$13.665$14.111.4M
Aug 28, 2026$14.915$15.00$14.20$14.671.1M
Aug 27, 2026$15.44$15.77$14.82$14.91717.74K
Aug 26, 2026$15.50$15.67$15.04$15.56717.88K
Aug 25, 2026$15.69$16.34$15.415$15.72919.12K
Aug 24, 2026$15.68$15.83$14.35$15.391.47M
Aug 21, 2026$16.32$16.91$15.33$15.83921.17K
Aug 20, 2026$16.50$16.71$15.63$16.101.63M
Aug 19, 2026$15.21$16.93$14.89$16.761.97M
Aug 18, 2026$14.25$15.04$13.91$14.722.32M
Aug 17, 2026$12.20$15.025$12.10$14.5453.45M
Aug 14, 2026$11.63$12.35$11.26$12.19773.77K
Aug 13, 2026$11.93$12.05$11.34$11.65707.43K

Latest FDMT news

The latest Smart Investors Daily articles mentioning FDMT.

Stock researchCompany · Overview

FDMT research

Overview

Company profile and research snapshot.

Company profile

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.33
Implied upside
—
Analysts
—
FDMT recent ratings
DateFirmRatingTarget
Jul 31, 2026B. Riley SecuritiesBuy—
Jul 20, 2026HC Wainwright & Co.Buy—
Mar 20, 2026HC Wainwright & Co.Buy—
Mar 19, 2026RBC CapitalOutperform—
Mar 19, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 25, 2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference: Wednesday, September

Yahoo · Aug 14, 2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 11, 2026, the compensation committee of the Company’s board of directors granted five new non-executive employees 35,200 Restricted Stock Units (RSUs). The RSUs

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By